title: Peptide receptor radionuclide therapy for advanced neuroendocrine tumors.
abstract: Peptide receptor radionuclide therapy (PRRT) consists of the systemic administration of a synthetic peptide, labeled with a suitable β-emitting radionuclide, able to irradiate tumors and their metastases via internalization through a specific receptor (usually somatostatin S2), over-expressed on the cell membrane. After almost 2 decades of experience, PRRT, with either (90)Y-octreotide or (177)Lu-octreotate, has established itself to be an efficient and effective therapeutic modality. As a treatment, it is relatively safe up to the known thresholds of absorbed and bio-effective isotope dosages and the renal and hematological toxicity profiles are acceptable if adequate protective measures are undertaken.
authors: Division of Nuclear Medicine, European Institute of Oncology, via Ripamonti 435, Milan 20141, Italy. Electronic address: lisa.bodei@ieo.it.
authors: Lisa
authors: L
authors: Bodei
authors: Division of Health Physics, European Institute of Oncology, via Ripamonti 435, Milan 20141, Italy.
authors: Marta
authors: M
authors: Cremonesi
authors: Department of Surgery, Yale School of Medicine, 310 Cedar Street, New Haven, CT 06520, USA.
authors: Mark
authors: M
authors: Kidd
authors: Division of Nuclear Medicine, European Institute of Oncology, via Ripamonti 435, Milan 20141, Italy.
authors: Chiara M
authors: CM
authors: Grana
authors: Radiometabolic Unit, Department of Nuclear Medicine, IRST-IRCCS, Via Maroncelli 40, Meldola 47014, Italy.
authors: Stefano
authors: S
authors: Severi
authors: Department of Surgery, Yale School of Medicine, 310 Cedar Street, New Haven, CT 06520, USA; Clifton Life Sciences, Branford, CT 06405, USA.
authors: Irvin M
authors: IM
authors: Modlin
authors: Division of Nuclear Medicine, European Institute of Oncology, via Ripamonti 435, Milan 20141, Italy; Radiometabolic Unit, Department of Nuclear Medicine, IRST-IRCCS, Via Maroncelli 40, Meldola 47014, Italy.
authors: Giovanni
authors: G
authors: Paganelli
mesh_terms: D006801:Humans; D018358:Neuroendocrine Tumors / Q000532:radiotherapy*; D015282:Octreotide / Q000627:therapeutic use*; D011868:Radioisotopes / Q000627:therapeutic use*; D018000:Receptors, Peptide / Q000627:therapeutic use*
chemical_list: D011868:Radioisotopes; D018000:Receptors, Peptide; D015282:Octreotide
keywords: Bone marrow; Bronchopulmonary; Carcinoid; Gastroenteropancreatic neuroendocrine tumor; Hepatic neuroendocrine metastasis; PRRT; Peptide receptor radionuclide therapy; Renal toxicity